The acquired hemophilia treatment is majorly dependent on dual objectives of hemostasis and inhibitor elimination. Immunological malfunctions triggered by factor infusion is a major challenge, often leading to surged instances of fatality. Acquired hemophilia is a very rare clinical condition, hence often demonstrating therapeutic constraints in disease management. Acquired hemophilia is identified by the rampant blood loss triggered by flawed immune response.
The condition is mainly cited amongst older adults who often remain victims of associated disease conditions. Additionally, post-partum mothers in several occasions have represented a decent chunk of affected patient burden of acquired hemophilia. In this condition, autoimmune factors fail to identify proteins in the body and identify them wrongly as foreign bodies. These factors lead to instances of skin lesions and hemorrhage within the body.
If remained undiagnosed and untreated for too long, the condition may result in early death. Therefore, several studies are being carried out to find an ideal solution of the treatment of acquired hemophilia, thereby paving way for million dollar opportunities in acquired hemophilia treatment market.
Geriatric Population Tend to be More Susceptible to Acquiring Hemophilia with No Previous History of Hemorrhage
The disease is a sparsely occurring autoimmune deficiency leading to hemorrhage. Immunosuppressant make up for most of the treatment besides other promising treatment solutions such as bypassing therapy. This is rightly done by permanent removal of autoantibody aided by adoption of immunosuppressant. Some of the potential bottlenecks identified in acquired hemophilia treatment market are faulty diagnosis and high prevalence of complications that subsequently lead to errors in immunosuppressive therapies.
Bypassing agents have the potential to induce blood coagulation amongst patients with acquired hemophilia that restricts production of thrombin.
As geriatric population is on the rise, frequent instances of acquired hemophilia is likely to gain momentum, with older adults being most susceptible. Both male and female populations remain equally vulnerable to acquired hemophilia, unlike general hemophilia cases which majorly is a genetic deficiency affecting male children.
However, drug potential and pipeline novelty is highly limited in acquired hemophilia cases, on the back of deficient R&D endeavors and minimal investments in disease analysis. However, in recent years, several frontline drug developers have been identified to have invested significantly in collaborations and business mergers to pursue R&D ventures in order to pioneer novel drug formulation. These occasional developments are poised to trigger tremendous growth in acquired hemophilia treatment market in the coming years.
Comments